CasLoc logo
All Cases PTAB Litigations UPC Oppositions

Tris Pharma Inc. v. Par Pharmaceutical Inc.

1:15-cv-00068

Overview

Case Number 1:15-cv-00068
Filing Date 2015-01-21
Status Terminated
Termination Date 2015-11-02
Court District Court, D. Delaware (ded)
Nature of Suit 830 Patent
Jurisdiction Type Federal Question
Cause of Action 35:271 Patent Infringement
Jury Demand None

Parties

Defendant

Par Pharmaceutical Inc. Operating Company

Represented By

5 Attorneys Listed

Katharine Lester Mowery

Richards, Layton & Finger, PA

Tel: +1 (302) 651-7623

Richards, Layton & Finger, PA, One Rodney Square

Jennifer Koh

Email: jennifer.koh@lw.com

Gregory K. Sobolski

Email: gregory.sobolski@lw.com

Brenda L. Danek

Email: brenda.danek@lw.com

Steven J. Fineman

Richards, Layton & Finger, PA

Tel: +1 (302) 658-6541

Richards, Layton & Finger, PA, One Rodney Square

Par Pharmaceutical Companies Inc. Operating Company

Represented By

2 Attorneys Listed

Katharine Lester Mowery

Richards, Layton & Finger, PA

Tel: +1 (302) 651-7623

Richards, Layton & Finger, PA, One Rodney Square

Steven J. Fineman

Richards, Layton & Finger, PA

Tel: +1 (302) 658-6541

Richards, Layton & Finger, PA, One Rodney Square

Plaintiff

Tris Pharma Inc. Operating Company

Represented By

3 Attorneys Listed

Jordan P. Markham

Email: jmarkham@milbank.com

Derek James Fahnestock

Morris, Nichols, Arsht & Tunnell LLP

Tel: +1 (302) 658-9200

1201 North Market Street, P.O. Box 1347

Jack B. Blumenfeld

Morris, Nichols, Arsht & Tunnell LLP

Tel: +1 (302) 658-9200

1201 North Market Street, P.O. Box 1347

Court & Judges

Court

District Court, D. Delaware (ded)

Global Patent Family Cross-Litigation Radar

CasLoc 360Β° Radar

Multi-jurisdiction dispute tracking across USPTO PTAB, U.S. Federal Courts, Unified Patent Court (UPC), and EPO Oppositions

πŸ‡ΊπŸ‡Έ
U.S. District Courts 1 proceeding
πŸ›οΈ
USPTO PTAB Trials Counterparts in force
πŸ‡ͺπŸ‡Ί
Unified Patent Court (UPC) Counterparts in force
πŸ‡©πŸ‡ͺ
European Patent Office (EPO) Counterparts in force
Parallel Proceedings Across Jurisdictions (1 found):
U.S. Courts: 1
U.S. District Court 2014-10-15
1:14-cv-01309

Tris Pharma Inc. v. Actavis Laboratories FL Inc.

Asserted Patent
Status: DED
Stay ahead of cross-border rulings. Subscribe for free automated docket alerts across U.S. Courts, PTAB, UPC, and EPO.

Patents Involved

5 Patents

There are 5 patents involved in this case.

Patent Asset Filing & Issue Date Expiration & Term Status External Links
US8062667
Modified release formulations containing drug-ion exchange resin complexes
Filed: 2007-03-15
Issued: 2011-11-22
Active (2.4 yrs remaining) +745d PTA
Expires: 2029-03-29
US8827903
Modular tool heads for use with circular surgical instruments
Filed: 2011-07-13
Issued: 2014-09-09
Active (5.2 yrs remaining) +206d PTA
Expires: 2032-02-04
US8465765
Orally effective methylphenidate extended release powder and aqueous suspension product
Filed: 2012-09-12
Issued: 2013-06-18
Active (5.8 yrs remaining)
Expires: 2032-09-12
US8563033
Orally effective methylphenidate extended release powder and aqueous suspension product
Filed: 2013-05-30
Issued: 2013-10-22
Active (6.5 yrs remaining)
Expires: 2033-05-30
US8778390
Orally effective methylphenidate extended release powder and aqueous suspension product
Filed: 2013-09-03
Issued: 2014-07-15
Active (6.8 yrs remaining)
Expires: 2033-09-03

Patent Enforceability & Injunction Risk Assessment

Statutory Analysis
Injunction Viability (35 U.S.C. Β§ 283) Active Threat

Active Threat β€” Patent is within enforceable statutory term. Patentee retains legal standing to seek permanent injunctive relief and exclusion orders.

Terminal Disclaimer & Cellect Risk Scrutiny / Risk

High PTA (+745 days) / Cellect Scrutiny β€” Over 745 days of PTA awarded. Susceptible to In re Cellect double patenting invalidation if continuation patents in the same family expire earlier.

Damages Lookback Horizon 6-Yr Max Lookback

Under 35 U.S.C. Β§ 286, damages cannot accrue for infringement prior to 6 years before filing. All Statutory Maintenance Fees Paid (12-Year Window Cleared).

Docket Entries

(25 total)
Pleading / Complaint

COMPLAINT filed against Par Pharmaceutical Companies Inc., Par Pharmaceutical Inc. - Magistrate Consent Notice to Pltf. ( Filing fee $ 400, receipt number 311-1659996.) - filed by Tris Pharma Inc.. (Attachments: # 1 Exhibit A - E, # 2 Civil Cover Sheet)(dmp, ) (Entered: 01/22/2015)

Entry #1 • 2015-01-21
1
Pleading / Complaint

COMPLAINT filed against Par Pharmaceutical Companies Inc., Par Pharmaceutical Inc. - Magistrate Consent Notice to Pltf. ( Filing fee $ 400, receipt number 311-1659996.) - filed by Tris Pharma Inc.. (Attachments: # 1 Exhibit A - E, # 2 Civil Cover Sheet)(dmp, ) (Entered: 01/22/2015)

Entry #1 • 2015-01-21
2
Pleading / Complaint

COMPLAINT filed against Par Pharmaceutical Companies Inc., Par Pharmaceutical Inc. - Magistrate Consent Notice to Pltf. ( Filing fee $ 400, receipt number 311-1659996.) - filed by Tris Pharma Inc.. (Attachments: # 1 Exhibit A - E, # 2 Civil Cover Sheet)(dmp, ) (Entered: 01/22/2015)

Entry #1 • 2015-01-21
2

Notice, Consent and Referral forms re: U.S. Magistrate Judge jurisdiction. (dmp, ) (Entered: 01/22/2015)

Entry #2 • 2015-01-21
1

Supplemental information for patent cases involving an Abbreviated New Drug Application (ANDA) - Date Patentee(s) Received Notice: 12/23/2014. Date of Expiration of Patent: SEE ATTACHED FORM.Thirty Month Stay Deadline: 6/23/2017. (dmp, ) (Entered: 01/22/2015)

Entry #3 • 2015-01-21
1

Track Case Updates

Automated email notifications for new filings & decisions

Identifier: •

Free service • 1-click unsubscribe anytime • Powered by CasLoc